There were two studies investigated young breast cancer patients undergoing NACT with anthracyclines/taxanes-based NACT regimens with or without targeted anti-HER-2 agents, pCR rate was 20.3% (7) and 20.9% (45), respectively, which were similar to our study data (23.7%). This evidence concerns the gene ERBB2 and breast cancer.